PBAC's latest decision on Insulin lispro: Recommended (2017). Considered for Treatment of type 1 and type 2 diabetes mellitus in patients who require higher daily insulin doses of >20 U.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with type 1 and type 2 diabetes mellitus who require insulin for maintenance of normal glucose homeostasis, specifically those requiring higher daily insulin doses of >20 U.
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Surrogate
Comparator
insulin lispro 100 units/mL (Humalog U100)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis on a per-unit insulin basis; no ICER calculated as this was a minor submission (formulation/strength change).